Clinical specimens from lung cancer patients demonstrate the up-regulation of B-cell lymphoma 2 (Bcl-2), an anti-apoptosis protein that plays a crucial role in drug resistance [30–32]. This evidence concerns the gene BCL2 and lung carcinoma.